{
    "clinical_study": {
        "@rank": "92385", 
        "arm_group": {
            "arm_group_label": "radiotherapy (SABR) plus pentoxifylline", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The objective of this prospective phase II protocol is to assess the toxicity and efficacy\n      of pentoxifylline and SABR in the re-treatment of recurrent or new lung cancers"
        }, 
        "brief_title": "Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancers", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "3.1 Inclusion Criteria: - Eligibility Criteria\n\n        3.1.1 Age >/= 18 years\n\n        3.1.2 ECOG performance status 0-1 3.1.3 Histologically proven diagnosis of a prior\n        thoracic malignancy treated with thoracic external beam radiotherapy with or without\n        systemic chemotherapy\n\n        3.1.4 Pathologic or clinical diagnosis of a new or loco-regional recurrent lung\n        malignancy.  A reasonable attempt should be made to make a pathologic diagnosis of\n        malignancy (ie. bronchoscopy, CT guided lung biopsy)\n\n          -  Loco-regional is defined as recurrence within the region of the primary tumor or\n             adjacent draining lymph node regions.\n\n          -  The new lesion or loco-regional recurrence must be within or adjacent to the\n             previously irradiated treatment volume.\n\n        3.1.5 Imaging as follows:\n\n          -  CT scan of the chest with IV contrast within 8 weeks of registration\n\n          -  Whole body PET scan within 8 weeks of registration\n\n        3.1.6 Pulmonary function test (PFTs), including diffusion capacity within 8 weeks of\n        registration\n\n        3.1.7 Negative serum pregnancy test within 2 weeks prior to registration for women of\n        childbearing potential.\n\n        3.1.6 Women of childbearing potential and male participants who are sexually     active\n        must agree to use a medically effective means of birth control\n\n        3.1.7   Patients must provide study specific informed consent prior to study entry.\n\n        Exclusion Criteria:\n\n        - 3.2 Exclusion Criteria\n\n        3.2.1. No previously reported thoracic radiotherapy\n\n        3.2.2.  FEV1 <20% predicted and/or  DLCO <20% predicted\n\n        3.2.2. Pregnant women or lactating women\n\n        3.2.3 Chemotherapy within 4 weeks of the initiation of SABR\n\n        3.2.4    Plans to administer systemic chemotherapy overlapping with radiotherapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "59", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871454", 
            "org_study_id": "BCC-RAD-13-Pentoxifylline"
        }, 
        "intervention": [
            {
                "arm_group_label": "radiotherapy (SABR) plus pentoxifylline", 
                "intervention_name": "stereotactic ablative radiotherapy (SABR)", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "radiotherapy (SABR) plus pentoxifylline", 
                "intervention_name": "Pentoxifylline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pentoxifylline", 
                "Vitamin E", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "teresa.roberts@louisville.edu", 
                "last_name": "Teresa L Roberts, RN", 
                "phone": "502-333-6934"
            }, 
            "facility": {
                "address": {
                    "city": "Louisville", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40202"
                }, 
                "name": "James Graham Brown Cancer Center, U of Louisville"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Effect of Pentoxifylline and Vitamin E in Preventing Radiation-induced Toxicity in the Treatment of Recurrent or New Primary Non-small Cell Lung Cancers Using Stereotactic Ablative Radiotherapy (SABR) in Patients Previously Treated With Thoracic Radiation", 
        "overall_official": {
            "affiliation": "James Graham Brown Cancer Center-U of Louisville", 
            "last_name": "Neal E Dunlap, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "primary endpoint is to estimate overall treatment-related toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "36 months-end of trial"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871454"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Estimate progression free survival", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Estimate tumor failure", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "estimate overall survival", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "James Graham Brown Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Louisville", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "James Graham Brown Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}